The Effect of the Chinese Medicine Juzen-taiho-to on Anemia in Dahl Salt-sensitive Rat
We examined whether JTT would improve anemia in the Dahl salt-sensitive (DS) rat, a model of hypertensive CHF. (Source: Journal of Cardiac Failure)
Source: Journal of Cardiac Failure - September 18, 2014 Category: Cardiology Authors: Eri Manabe, Naoko Sasaki, Toshiyuki Shikata, Tohru Masuyama, Takeshi Tsujino Source Type: research
Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease
Conclusions
The study results suggest that hyporesponsiveness to ESA after the first 12-week administration as well as after 12 weeks is a risk for RD in pre-dialysis CKD patients. Furthermore, hyperphosphatemia and diabetic nephropathy are risk factors for RD. (Source: Clinical and Experimental Nephrology)
Source: Clinical and Experimental Nephrology - September 3, 2014 Category: Urology & Nephrology Source Type: research
Structure-based comprehensive identification of erythropoiesis-stimulating agents and their biosimilars
Abstract
Erythropoietin (EPO) is a glycoprotein that stimulates production of red blood cells. After the patents for recombinant EPO (epoetin) expired in 2007, biosimilar erythropoiesis-stimulating agents (ESAs) have become widely circulated in the black market. However, the heterogeneity of ESAs in the post-translational glycosylation hinders the identification of these compounds. In the present study, after cleaving N-linked glycans from tryptic peptides of ESAs with N-glycosidase F, we analyzed the resulting eight glycan-free peptides by liquid chromatography–electrospray ionization-tandem mass spe...
Source: Forensic Toxicology - August 1, 2014 Category: Forensic Medicine Source Type: research
Insufficient evidence exists to evaluate effects of blood transfusions and iron therapy for treatment of anaemia in patients with heart disease--erythropoietin agonists do not improve outcomes
Commentary on: Kansagara D, Dyer E, Englander H, et al.. Treatment of anemia in patients with heart disease: a systematic review. Ann Intern Med 2013;159:746–57. Context The prevalence of anaemia ranges from 20% to 40% in patients with coronary heart disease (CHD) and is nearly 50% in patients with chronic heart failure (CHF). Anaemia is an independent predictor of poor clinical outcomes in patients with heart disease.1 2 Targeting anaemia to improve clinical outcomes is therefore a logical inference, with recent interest being largely driven by trials evaluating erythropoietin stimulating agents (ESAs) and one tria...
Source: Evidence-Based Medicine - July 18, 2014 Category: Internal Medicine Authors: Samson, R., Le Jemtel, T. Tags: Clinical trials (epidemiology), Epidemiologic studies, Haematology (incl blood transfusion), Immunology (including allergy), Drugs: cardiovascular system, Hypertension, Ischaemic heart disease Therapeutics Source Type: research
Cost Savings Using a Protocol Approach to Manage Anemia in a Hemodialysis Unit.
Conclusion: The use of an anemia management protocol resulted in the deprescribing of DBO and iron agents while increasing the number of patients in the target Hgb range, which led to significant cost savings in the treatment of anemia. © 2014 S. Karger AG, Basel.
PMID: 24903565 [PubMed - as supplied by publisher] (Source: American Journal of Nephrology)
Source: American Journal of Nephrology - June 5, 2014 Category: Urology & Nephrology Authors: Charlesworth EC, Richardson RM, Battistella M Tags: Am J Nephrol Source Type: research
Long-acting erythropoietin stimulating agents for persistent anemia after kidney transplant: risk factors and outcome.
CONCLUSIONS: Anemia is an important problem after kidney transplant, and iron use is suboptimal in kidney transplant recipients. Darbepoetin alfa and continuous erythropoietin receptor activator had comparable positive results.
PMID: 24907722 [PubMed - in process] (Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation)
Source: Experimental and Clinical Transplantation : official journal of the Middle East Society for Organ Transplantation - June 1, 2014 Category: Transplant Surgery Authors: Al-Otaibi T, Gheith O, Halim MA, Abu Attia H, Mansour H, Said T, Nair P, Balaha M, Nampoory MR Tags: Exp Clin Transplant Source Type: research
The association between dose ratio at time of switch from darbepoetin alfa to peg-epoetin beta and transfusions in haemodialysis patients
(Source: American Journal of Kidney Diseases)
Source: American Journal of Kidney Diseases - April 14, 2014 Category: Urology & Nephrology Tags: National Kidney Foundation 2014 Spring Clinical Meetings Abstracts Source Type: research
Effects of ramipril and darbepoetin on electromechanical activity of the heart in doxorubicin-induced cardiotoxicity
Cardiac toxicity is a deadly condition caused by impaired cardiac activity similar to congestive heart failure (CHF). Doxorubicin (DOX) is a potent anticancer drug having a potential of myocardial damage . Doxorubicin induced experimental toxicity has been characterized by heart failure and anaemia . In human patients, risks for the use of anthracyclines have been reported associated with cardiac death which is the most prevalent of QT prolongation that triggered Torsades de Pointes . The anaemia of CHF patient is evidently due to the excessive cytokine production . Pre-treatment with erythropoietin hormone alone protected...
Source: International Journal of Cardiology - April 7, 2014 Category: Cardiology Authors: Yunusemre Ozkanlar, Mustafa Sinan Aktas, Mehmet Turkeli, Nergis Erturk, Ertan Oruc, Seckin Ozkanlar, Akin Kirbas, Burak Erdemci, Enbiya Aksakal Tags: Letters to the Editor Source Type: research
Erythropoietin‐stimulating agents in the management of anemia of end‐stage renal disease patients on regular hemodialysis: A prospective randomized comparative study from Qatar
This study has specifically compared the effect of ESA type on the variability of serum hemoglobin levels in hemodialysis patients. Furthermore, it confirmed the efficacy and safety of once monthly CERA for maintaining tight hemoglobin control within recommended target ranges. (Source: Hemodialysis International)
Source: Hemodialysis International - April 1, 2014 Category: Hematology Authors: Fadwa Saqr Al‐Ali, Mohamed El‐Sayed Abdelfattah, Ashraf Ahmed Fawzy, Ahmed Farouk Hamdy, Aisha Elsayed Abdulla Tags: Original Article Source Type: research
Darbepoetin for the anaemia of chronic kidney disease.
CONCLUSIONS: Data suggest that darbepoetin alfa effectively reduces need for blood transfusions in adults with CKD stage 3 to 5, but has little or no effect on mortality or quality of life. The effects of darbepoetin alfa in adults with CKD stage 5D and kidney transplant recipients and children with CKD remain uncertain as do the relative benefits and harms of darbepoetin alfa compared with other ESAs (epoetin alfa or beta and methoxy polyethylene glycol-epoetin beta).
PMID: 24683046 [PubMed - as supplied by publisher] (Source: Cochrane Database of Systematic Reviews)
Source: Cochrane Database of Systematic Reviews - March 31, 2014 Category: Journals (General) Authors: Palmer SC, Saglimbene V, Craig JC, Navaneethan SD, Strippoli GF Tags: Cochrane Database Syst Rev Source Type: research
Dose Efficiency of Erythropoiesis-Stimulating Agents for the Treatment of Patients With Chemotherapy-Induced Anemia: A Systematic Review.
CONCLUSIONS: Statistical heterogeneity between studies was high, although clinically the studies represented medical practice. Without randomized clinical trials directly comparing darbepoetin alfa and short-acting ESAs, these findings are tentative and future research is warranted. This review shows that good-quality, reliable data from head-to-head trials are lacking. The best available evidence comes from prospective ESA-arm data. Mean weekly doses, dose increases, and dose decreases suggest a dose efficiency for darbepoetin alfa compared with short-acting ESAs.
PMID: 24656152 [PubMed - as supplied by publisher]...
Source: Clinical Therapeutics - March 18, 2014 Category: Drugs & Pharmacology Authors: Forbes CA, Worthy G, Harker J, Kleijnen J, Kutikova L, Zelek L, Van Belle S Tags: Clin Ther Source Type: research
Anemia Management Trends in Hospital-Based Dialysis Centers (HBDCs), 2010 to 2013.
CONCLUSIONS: These study results support growing evidence that meaningful changes have occurred over the last 3 years in how anemia is clinically managed in US hemodialysis patients. Study limitations include that changes in patient clinical/demographic characteristics over time were not controlled for and that study findings may not be applicable to HBDCs that have different patient populations and/or do not use an electronic medical record system. Continuing to evaluate anemia management practices in HBDCs would provide additional information on the risks and benefits of anemia care. Consistent with national data, the fi...
Source: Clinical Therapeutics - February 27, 2014 Category: Drugs & Pharmacology Authors: Coritsidis GN, Maglinte GA, Acharya A, Saxena A, Chang CL, Hill J, Gitlin M, Lafayette RA Tags: Clin Ther Source Type: research
Darbepoetin alfa once monthly corrects anaemia in patients with chronic kidney disease not on dialysis
ConclusionIn subjects with CKD‐ND, QM dosing was non‐inferior to Q2W dosing for anaemia correction and had a similar safety profile. (Source: Nephrology)
Source: Nephrology - February 1, 2014 Category: Urology & Nephrology Authors: Simon D. Roger, Elena Kolmakova, Maple Fung, Robert Malecki, José Vinhas, Frank Dellanna, Mark Thomas, Nick Manamley, Sándor Ferenczi Tags: Original Article Source Type: research
Final results from the prospective phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on event-free survival in early breast cancer
Conclusions
DA treatment did not impact EFS or OS in routine adjuvant BC treatment. (Source: Annals of Oncology)
Source: Annals of Oncology - December 19, 2013 Category: Cancer & Oncology Authors: Nitz, U., Gluz, O., Zuna, I., Oberhoff, C., Reimer, T., Schumacher, C., Hackmann, J., Warm, M., Uleer, C., Runde, V., Dunnebacke, J., Belzl, N., Augustin, D., Kates, R. E., Harbeck, N., on behalf of the West German Study Group Tags: original articles Source Type: research
Stable hemoglobin in hemodialysis patients: forest for the trees ¿ a 12-week pilot observational study
Conclusion:
The observation of 7.7 events per patient per month suggests a careful monitoring of Hb and DA dosing every other week, in order to maintain Hb level within the target. (Source: BMC Nephrology)
Source: BMC Nephrology - November 4, 2013 Category: Urology & Nephrology Authors: Jacques RottembourgFloride KpadeFadia TebibelAurélie DansaertGaelle Chenuc Source Type: research
